MX386615B - Vectores virales adenoasociados para el tratamiento de mucopolisacaridosis. - Google Patents

Vectores virales adenoasociados para el tratamiento de mucopolisacaridosis.

Info

Publication number
MX386615B
MX386615B MX2017015725A MX2017015725A MX386615B MX 386615 B MX386615 B MX 386615B MX 2017015725 A MX2017015725 A MX 2017015725A MX 2017015725 A MX2017015725 A MX 2017015725A MX 386615 B MX386615 B MX 386615B
Authority
MX
Mexico
Prior art keywords
treatment
adenoassorted
mucopolysaccharidosis
viral vectors
disordersand
Prior art date
Application number
MX2017015725A
Other languages
English (en)
Spanish (es)
Other versions
MX2017015725A (es
Inventor
Bosch Tubert Maria Fátima
Mallol Sandra Motas
Haurigot Virginia Areba
Original Assignee
UNIV AUTòNOMA DE BARCELONA
Esteve Pharmaceuticals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UNIV AUTòNOMA DE BARCELONA, Esteve Pharmaceuticals Sa filed Critical UNIV AUTòNOMA DE BARCELONA
Publication of MX2017015725A publication Critical patent/MX2017015725A/es
Publication of MX386615B publication Critical patent/MX386615B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0016Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the nucleic acid is delivered as a 'naked' nucleic acid, i.e. not combined with an entity such as a cationic lipid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y301/00Hydrolases acting on ester bonds (3.1)
    • C12Y301/06Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06013Iduronate-2-sulfatase (3.1.6.13)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/22Vectors comprising a coding region that has been codon optimised for expression in a respective host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2017015725A 2015-06-05 2016-06-03 Vectores virales adenoasociados para el tratamiento de mucopolisacaridosis. MX386615B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15382297.8A EP3101125A1 (en) 2015-06-05 2015-06-05 Adenoassociated virus vectors for the treatment of mucopolysaccharidoses
PCT/EP2016/062655 WO2016193431A1 (en) 2015-06-05 2016-06-03 Adenoassociated virus vectors for the treatment of mucopolysaccharidoses

Publications (2)

Publication Number Publication Date
MX2017015725A MX2017015725A (es) 2018-08-15
MX386615B true MX386615B (es) 2025-03-19

Family

ID=53398018

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017015725A MX386615B (es) 2015-06-05 2016-06-03 Vectores virales adenoasociados para el tratamiento de mucopolisacaridosis.

Country Status (21)

Country Link
US (1) US10617771B2 (https=)
EP (2) EP3101125A1 (https=)
JP (1) JP6850736B2 (https=)
KR (1) KR102609858B1 (https=)
CN (1) CN108138154B (https=)
AU (1) AU2016273343B2 (https=)
CA (1) CA2988201C (https=)
CL (1) CL2017003096A1 (https=)
CO (1) CO2017012562A2 (https=)
ES (1) ES2790834T3 (https=)
IL (1) IL255939B (https=)
MX (1) MX386615B (https=)
MY (1) MY184586A (https=)
NZ (1) NZ738018A (https=)
PH (1) PH12017502192B1 (https=)
PT (1) PT3303576T (https=)
RU (1) RU2744593C2 (https=)
TN (1) TN2017000506A1 (https=)
UA (1) UA125373C2 (https=)
WO (1) WO2016193431A1 (https=)
ZA (1) ZA201708039B (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2605798A1 (en) 2010-07-12 2013-06-26 Universidad Autònoma de Barcelona Gene therapy composition for use in diabetes treatment
EP2692868A1 (en) 2012-08-02 2014-02-05 Universitat Autònoma De Barcelona Adeno-associated viral (AAV) vectors useful for transducing adipose tissue
EP3194430A1 (en) 2014-09-16 2017-07-26 Universitat Autònoma De Barcelona Adeno-associated viral vectors for the gene therapy of metabolic diseases
US11085055B2 (en) 2014-12-05 2021-08-10 Universitat Autonoma De Barcelona Viral vectors for the treatment of diabetes
US11033638B2 (en) 2015-01-07 2021-06-15 Universität Autonoma De Barcelona Single-vector gene construct comprising insulin and glucokinase genes
SG10201912761UA (en) * 2016-04-15 2020-02-27 The Trustees Of The Univ Of Pennsyvania Gene therapy for treating mucopolysaccharidosis type ii
KR20190139951A (ko) 2017-04-14 2019-12-18 리젠엑스바이오 인크. 인간 뉴런 또는 신경교 세포에 의해 생성된 재조합 인간 이두로네이트-2 설파타제(ids)를 이용한 뮤코다당증 ii형의 치료
IL270882B2 (en) 2017-05-24 2024-02-01 Univ Barcelona Autonoma Viral expression vectors containing the coding sequence for FIBROBLAST GROWTH FACTOR 21 (FGF21
KR102883778B1 (ko) * 2017-09-22 2025-11-12 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 Ii형 점액다당류증의 치료를 위한 유전자 요법
CN108715867A (zh) * 2018-05-31 2018-10-30 深圳市免疫基因治疗研究院 一种Sanfilippo B综合症慢病毒载体、慢病毒及其制备方法和应用
CN108795985A (zh) * 2018-05-31 2018-11-13 深圳市免疫基因治疗研究院 一种黏多糖贮积症慢病毒载体、慢病毒及其制备方法和应用
EP3829619A4 (en) * 2018-07-27 2022-05-18 REGENXBIO Inc. TREATMENT OF IVA MUCOPOLYSACCHARIDOSIS
US12201095B2 (en) * 2018-11-15 2025-01-21 Esteve Pharmaceuticals, S.A. Animal model of mucopolysaccharidoses type IVA
AR118493A1 (es) * 2019-03-28 2021-10-20 Esteve Pharmaceuticals Sa Métodos para la fabricación de vectores virales recombinantes
ES2948620T3 (es) 2019-07-10 2023-09-14 Masonic Medical Res Laboratory Vgll4 con elemento regulador CIS de UCP-1 y método de uso del mismo
AU2020401116A1 (en) * 2019-12-10 2022-07-21 Takeda Pharmaceutical Company Limited Adeno associated virus vectors for the treatment of Hunter disease
IL296986A (en) * 2020-04-06 2022-12-01 Homology Medicines Inc Adeno-associated virus preparations for ids gene transfer and methods of use thereof
CN111718947B (zh) * 2020-06-18 2022-08-23 舒泰神(北京)生物制药股份有限公司 用于治疗ⅲa或ⅲb型粘多糖贮积症的腺相关病毒载体及用途
CN114480454B (zh) * 2020-10-27 2024-03-29 华东理工大学 用于治疗粘多糖贮积症ⅱ型的腺相关病毒载体、药物及其应用
EP4291249A2 (en) 2021-02-10 2023-12-20 RegenxBio Inc. Treatment of mucopolysaccharidosis ii with recombinant human iduronate-2-sulfatase (ids)
WO2022221421A2 (en) * 2021-04-13 2022-10-20 Capsida, Inc. Aav compositions with high brain expression for treating mucopolysaccharidosis ii
EP4389772A4 (en) * 2021-08-18 2025-08-20 Joint Stock Company Generium TARGETED ADMINISTRATION OF THERAPEUTIC FERMENTS

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100762945B1 (ko) * 2004-09-08 2007-10-04 진동규 동물 세포주를 이용한 이듀로네이트-설파타제의 발현 방법및 그 발현을 위한 세포주
CA2711590C (en) * 2008-01-18 2021-03-23 Biomarin Pharmaceutical Inc. Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
EP2485761B1 (en) * 2009-10-09 2019-02-27 Armagen, Inc. Methods and compositions for increasing iduronate 2-sulfatase activity in the cns
WO2011108451A1 (ja) * 2010-03-01 2011-09-09 日本ケミカルリサーチ株式会社 遺伝子ノックアウト細胞を用いた組換え体リソソーム酵素の製造方法
EP2394667A1 (en) * 2010-06-10 2011-12-14 Laboratorios Del Dr. Esteve, S.A. Vectors and sequences for the treatment of diseases
US20130236442A1 (en) * 2010-11-12 2013-09-12 Green Cross Corporation Iduronate-2-sulfatase and use thereof
WO2012101671A1 (en) * 2011-01-25 2012-08-02 Jcr Pharmaceuticals Co., Ltd. Method for production of human recombinant iduronate 2-sulfatase
EP3460064B8 (en) * 2011-04-03 2024-03-20 The General Hospital Corporation d/b/a Massachusetts General Hospital Efficient protein expression in vivo using modified rna (mod-rna)
CN104411338A (zh) * 2012-04-02 2015-03-11 现代治疗公司 用于产生与人类疾病相关的生物制剂和蛋白质的修饰多核苷酸
US9150841B2 (en) * 2012-06-29 2015-10-06 Shire Human Genetic Therapies, Inc. Cells for producing recombinant iduronate-2-sulfatase
DK3107562T3 (da) * 2014-02-19 2019-12-16 Bioasis Technologies Inc P97-ids-fusionsproteiner

Also Published As

Publication number Publication date
CA2988201A1 (en) 2016-12-08
MX2017015725A (es) 2018-08-15
CN108138154A (zh) 2018-06-08
CA2988201C (en) 2024-01-16
AU2016273343B2 (en) 2022-04-28
IL255939B (en) 2021-05-31
EP3303576B1 (en) 2020-02-12
ZA201708039B (en) 2018-11-28
WO2016193431A1 (en) 2016-12-08
NZ738018A (en) 2025-03-28
ES2790834T3 (es) 2020-10-29
US10617771B2 (en) 2020-04-14
US20180169272A1 (en) 2018-06-21
PH12017502192A1 (en) 2018-06-11
JP6850736B2 (ja) 2021-03-31
KR20180012843A (ko) 2018-02-06
MY184586A (en) 2021-04-06
RU2017142006A3 (https=) 2020-02-03
EP3303576A1 (en) 2018-04-11
BR112017025892A2 (pt) 2018-08-14
RU2744593C2 (ru) 2021-03-11
RU2017142006A (ru) 2019-07-09
EP3101125A1 (en) 2016-12-07
UA125373C2 (uk) 2022-03-02
IL255939A (en) 2018-01-31
JP2018517414A (ja) 2018-07-05
CL2017003096A1 (es) 2018-08-10
CN108138154B (zh) 2022-01-18
KR102609858B1 (ko) 2023-12-05
TN2017000506A1 (en) 2019-04-12
CO2017012562A2 (es) 2018-02-28
PT3303576T (pt) 2020-05-08
AU2016273343A1 (en) 2017-12-21
PH12017502192B1 (en) 2022-09-02

Similar Documents

Publication Publication Date Title
MX386615B (es) Vectores virales adenoasociados para el tratamiento de mucopolisacaridosis.
MX383227B (es) Vectores de virus adenoasociados para el tratamiento de trastornos de almacenamiento lisosomico.
MX378273B (es) Compuestos activos hacia bromodominios.
MX2022004304A (es) Agentes inductores de apoptosis.
EA201891200A1 (ru) Композиции, содержащие бактериальные штаммы
AR109752A1 (es) Vectores de virus adenoasociados para el tratamiento de mucopolisacaridosis
CL2016001889A1 (es) (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1.
PH12019501097A1 (en) Magl inhibitors
EA201792500A1 (ru) Aav-опосредованная экспрессия антител против гриппа и способы их использования
PH12016501873A1 (en) Anti-influenza b virus hemagglutinin antibodies and methods of use
PH12019501102A1 (en) Magl inhibitors
MX388752B (es) Composiciones novedosas, usos y métodos para hacerlas.
MX2018004674A (es) Moduladores de interacción de sestrina-gator2 y sus usos.
CL2018000565A1 (es) Compuestos derivados de piridinona dicarboxamida, inhibidores de bromodominio; composicion farmaceutica; combinacion farmaceutica; utiles en el tratamiento de enfermedades autoinmunitarias, inflamatorias, virales y cancer, entre otras.
EA201791454A1 (ru) Лекарственные формы для трансдермального введения
PH12017500348B1 (en) Tetrahydroquinoline derivatives as bromodomain inhibitors
EA201792262A1 (ru) Пироглутамат вортиоксетина
BR112017024908A2 (pt) usos terapêuticos da 4-cloroquinurenina
HUE057871T2 (hu) Gyógyászati hatóanyagokat tartalmazó hialuronán konjugátumok, eljárások és kompozíciók
MX382092B (es) Compuestos heterocíclicos para el tratamiento de enfermedades.
BR112017004552A2 (pt) composições farmacêuticas
EA201700254A1 (ru) Комбинация
MA40642A (fr) Nouveaux dérivés peptidiques et leurs utilisations
EA201891848A1 (ru) Фармацевтическая композиция для применения в лечении фиброза
EA201791483A1 (ru) Фармацевтическая композиция для лечения микоза